Human binding molecules having killing activity against enterococci
AssigneeJanssen Vaccines & Prevention B.V.
InventorsMark Throsby, Robert A. Kramer, Cornelis A. de Kruif
Life of this patent
Estimating the term…
Abstract
Described are human binding molecules specifically binding to enterococci and having killing activity against enterococci, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the molecules. The molecules can be used, for example, in the diagnosis, prophylaxis, and/or treatment of a condition resulting from Enterococcus.
Claims13
A human monoclonal antibody having opsonic phagocytic killing activity against at least one strain of each of at least two different Enterococcus species and against at least one strain of Staphylococcus aureus, wherein the human monoclonal antibody comprises:
- a heavy chain CDR1 comprising SEQ ID NO:326,
- a heavy chain CDR2 comprising SEQ ID NO:327,
- a heavy chain CDR3 comprising SEQ ID NO:328,
- a light chain CDR1 comprising SEQ ID NO:329,
- a light chain CDR2 comprising SEQ ID NO:330, and
- a light chain CDR3 comprising SEQ ID NO:331.
Dependencies are inferred from the claim text.